Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MLYS Mineralys Therapeutics	$15.73 +0.4%	$14.40	$8.24 ▼ $18.38	$1.03B	-0.3	494,611 shs	1.16 million shs
MRUS Merus	$55.69 +0.6%	$43.29	$33.19 ▼ $61.28	$3.88B	0.94	728,690 shs	1.83 million shs
RYTM Rhythm Pharmaceuticals	$61.36 -0.8%	$59.55	$36.27 ▼ $68.58	$3.90B	2.36	553,646 shs	484,159 shs
SRPT Sarepta Therapeutics	$37.72 -2.3%	$50.84	$34.10 ▼ $173.25	$3.71B	0.85	1.73 million shs	3.09 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MLYS Mineralys Therapeutics	0.00%	-1.44%	+2.01%	+75.95%	+23.18%
MRUS Merus	0.00%	+1.00%	+26.02%	+22.48%	+4.60%
RYTM Rhythm Pharmaceuticals	0.00%	-1.60%	-4.14%	+17.10%	+71.97%
SRPT Sarepta Therapeutics	0.00%	-0.47%	-40.61%	-62.73%	-70.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MLYS Mineralys Therapeutics	2.8443 of 5 stars	3.5	1.0	0.0	3.4	5.0	0.0
MRUS Merus	2.883 of 5 stars	4.6	2.0	0.0	2.7	1.7	0.0
RYTM Rhythm Pharmaceuticals	3.8948 of 5 stars	3.5	1.0	4.3	3.9	0.8	0.6
SRPT Sarepta Therapeutics	4.7709 of 5 stars	4.4	2.0	4.2	2.7	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MLYS Mineralys Therapeutics	3.00	Buy	$38.00	141.58% Upside
MRUS Merus	3.13	Buy	$86.00	54.43% Upside
RYTM Rhythm Pharmaceuticals	3.00	Buy	$76.62	24.86% Upside
SRPT Sarepta Therapeutics	2.83	Moderate Buy	$122.61	225.05% Upside

Current Analyst Ratings Breakdown

Latest MLYS, RYTM, MRUS, and SRPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	RYTM Rhythm Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $94.00
5/23/2025	MRUS Merus	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
5/22/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$40.00 ➝ $40.00
5/20/2025	SRPT Sarepta Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$169.00 ➝ $84.00
5/19/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
5/14/2025	MLYS Mineralys Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00
5/13/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
5/8/2025	MRUS Merus	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$91.00 ➝ $89.00
5/8/2025	SRPT Sarepta Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy	$188.00 ➝ $85.00
5/8/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$115.00 ➝ $100.00
5/8/2025	SRPT Sarepta Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Inline	$50.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
MRUS Merus	$54.73M	70.43	N/A	N/A	$6.17 per share	9.03
RYTM Rhythm Pharmaceuticals	$136.86M	28.52	N/A	N/A	$2.87 per share	21.38
SRPT Sarepta Therapeutics	$2.23B	1.66	N/A	N/A	$9.19 per share	4.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MLYS Mineralys Therapeutics	-$177.81M	-$3.73	N/A	N/A	N/A	N/A	-67.97%	-62.40%	8/12/2025 (Estimated)
MRUS Merus	-$154.94M	-$4.08	N/A	N/A	N/A	-680.61%	-38.89%	-31.16%	7/30/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$184.68M	-$2.81	N/A	N/A	N/A	-230.07%	-367.36%	-77.47%	8/5/2025 (Estimated)
SRPT Sarepta Therapeutics	-$535.98M	-$2.69	30.18	3.45	N/A	7.43%	11.00%	3.35%	8/6/2025 (Estimated)

Latest MLYS, RYTM, MRUS, and SRPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million
5/12/2025	Q1 2025	MLYS Mineralys Therapeutics	-$1.02	-$0.79	+$0.23	-$0.79	N/A	N/A
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million
5/6/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	-$3.42	-$5.62	-$4.60	$685.75 million	$744.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MLYS Mineralys Therapeutics	N/A	14.02	14.02
MRUS Merus	N/A	8.32	8.32
RYTM Rhythm Pharmaceuticals	N/A	3.49	3.34
SRPT Sarepta Therapeutics	0.93	3.84	3.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MLYS Mineralys Therapeutics	84.46%
MRUS Merus	96.14%
RYTM Rhythm Pharmaceuticals	N/A
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
MLYS Mineralys Therapeutics	25.56%
MRUS Merus	4.57%
RYTM Rhythm Pharmaceuticals	6.10%
SRPT Sarepta Therapeutics	7.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MLYS Mineralys Therapeutics	28	65.18 million	33.27 million	Optionable
MRUS Merus	37	69.21 million	65.34 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	58.02 million	Optionable
SRPT Sarepta Therapeutics	840	98.28 million	88.17 million	Optionable

MLYS, RYTM, MRUS, and SRPT Headlines

Recent News About These Companies

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Recommendation of "Moderate Buy" from Analysts

June 1 at 1:31 AM | marketbeat.com

Mackenzie Financial Corp Has $2.83 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

May 31 at 4:27 AM | marketbeat.com

StockWatch: Intellia Stumbles on News of Patient’s Severe Liver Toxicity

May 30 at 3:55 PM | genengnews.com

Q2 Earnings Forecast for SRPT Issued By Zacks Research

May 30 at 7:51 AM | marketbeat.com

Research Analysts Set Expectations for SRPT Q2 Earnings

May 30 at 1:18 AM | americanbankingnews.com

D. E. Shaw & Co. Inc. Sells 11,389,239 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

May 28, 2025 | marketbeat.com

Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)?

May 27, 2025 | insidermonkey.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $36.39 Million Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

May 27, 2025 | marketbeat.com

Two Sigma Investments LP Has $9.13 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

May 27, 2025 | marketbeat.com

46,986 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Purchased by Woodline Partners LP

May 26, 2025 | marketbeat.com

HC Wainwright Reaffirms "Neutral" Rating for Sarepta Therapeutics (NASDAQ:SRPT)

May 25, 2025 | americanbankingnews.com

Sarepta Therapeutics (NASDAQ:SRPT) Receives "Neutral" Rating from HC Wainwright

May 24, 2025 | marketbeat.com

Sarepta Therapeutics Analyst Ratings and Price Targets | NASDAQ:SRPT | Benzinga

May 23, 2025 | benzinga.com

Sarepta Therapeutics Analyst Ratings and Price Targets | NASDAQ:SRPT | Benzinga

May 23, 2025 | benzinga.com

Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up - Still a Buy?

May 23, 2025 | marketbeat.com

JPMorgan Chase & Co. Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $84.00

May 23, 2025 | americanbankingnews.com

FDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne study

May 22, 2025 | biopharmadive.com

Sarepta Can Start Dosing Elevidys Trial, UK Regulators Say

May 22, 2025 | precisionmedicineonline.com

Sarepta Therapeutics Stock Gains After U.K. Lets Elevidys Study Continue

May 21, 2025 | marketwatch.com

Sarepta, Roche get U.K. feedback to lift clinical hold on Elevidys' Duchenne trial

May 21, 2025 | msn.com

Sarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne

May 21, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLYS, RYTM, MRUS, and SRPT Company Descriptions

Mineralys Therapeutics NASDAQ:MLYS

$15.73 +0.07 (+0.45%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$15.58 -0.15 (-0.95%)

As of 07:48 AM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Merus NASDAQ:MRUS

$55.69 +0.32 (+0.58%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$56.07 +0.38 (+0.68%)

As of 08:21 AM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Rhythm Pharmaceuticals NASDAQ:RYTM

$61.36 -0.52 (-0.84%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$61.33 -0.03 (-0.05%)

As of 08:00 AM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Sarepta Therapeutics NASDAQ:SRPT

$37.72 -0.89 (-2.31%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$37.60 -0.12 (-0.32%)

As of 08:37 AM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time